The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 14, 2026
Filed:
Mar. 28, 2022
Applicant:
Trx Biosciences Limited, London, GB;
Inventors:
Assignee:
TRx Biosciences Limited, London, GB;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 47/14 (2017.01); A61K 31/00 (2006.01); A61K 31/12 (2006.01); A61K 31/192 (2006.01); A61K 31/196 (2006.01); A61K 31/216 (2006.01); A61K 31/4025 (2006.01); A61K 31/4184 (2006.01); A61K 31/436 (2006.01); A61K 31/44 (2006.01); A61K 31/4418 (2006.01); A61K 31/4453 (2006.01); A61K 31/496 (2006.01); A61K 31/502 (2006.01); A61K 31/5377 (2006.01); A61K 31/553 (2006.01); A61K 31/58 (2006.01); A61K 31/7135 (2006.01); A61K 38/12 (2006.01); A61K 47/12 (2006.01); A61K 47/28 (2006.01);
U.S. Cl.
CPC ...
A61K 47/14 (2013.01); A61K 31/12 (2013.01); A61K 31/192 (2013.01); A61K 31/196 (2013.01); A61K 31/216 (2013.01); A61K 31/4025 (2013.01); A61K 31/4184 (2013.01); A61K 31/436 (2013.01); A61K 31/44 (2013.01); A61K 31/4418 (2013.01); A61K 31/4453 (2013.01); A61K 31/496 (2013.01); A61K 31/502 (2013.01); A61K 31/5377 (2013.01); A61K 31/553 (2013.01); A61K 31/58 (2013.01); A61K 31/658 (2023.05); A61K 31/7135 (2013.01); A61K 38/12 (2013.01); A61K 47/28 (2013.01);
Abstract
The present specification discloses pharmaceutical composition disclosed herein comprises one or more therapeutic compounds, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free Cfatty acids, one or more free Cfatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more therapeutic compounds into the disclosed pharmaceutical compositions.